Therefore, in this study, we aimed to investigate the following in ESCC patients: (1) the status of MLKL and pMLKL in pre- and post-NAC specimens, and their correlation with the clinical outcome/therapeutic efficacy of NAC; and (2) the correlation between these necroptotic markers and TILs, examined by CD3, CD8, and FOXP3 immunolocalization in ESCC patients. The gene discussed is CD8A; the disease is esophageal squamous cell carcinoma.